Press Release

October 8 2024

Verismo Therapeutics Announces the Activation of its CELESTIAL-301 Clinical Trial at Colorado Blood Cancer Institute

MORE >

September 17 2024

Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant

MORE >

May 14 2024

Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL

MORE >

May 6 2024

Verismo Therapeutics Announces Upcoming Presentation at ASGCT 2024

MORE >

April 3 2024

Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL

MORE >

March 7 2024

Verismo Therapeutics Announces Opening of Second Clinical Site for STAR-101 Phase 1 Trial

MORE >

November 3 2023

Verismo Therapeutics Announces Upcoming Presentation at SITC 2023

MORE >

September 6 2023

Verismo Therapeutics Doses First Patient in Groundbreaking SynKIR-110 Clinical Trial for Advanced Cancers

MORE >

August 22 2023

Verismo Therapeutics and University of Pennsylvania Discover Two Novel Binders Targeting CD19; Enter Licensing Agreement

MORE >

July 11 2023

Verismo Therapeutics Welcomes Dr. Mala Talekar as Vice President of Clinical Development

MORE >